Ahlan's Profile
Ahlan's Posts
Somebody's knocking on Augen's door.
April 27, 2011
Goldeye to Commence Drilling at Shining Tree Gold Project
Hires Coordinator of Investor Relations
TORONTO, ONTARIO--(Marketwire - April 27, 2011) - Goldeye Explorations Limited ("Goldeye" or "the Company") (TSX VENTURE:GGY) is pleased to announce that a 2,500 to 3,000 metre diamond drilling program will commence on April 27, 2011 on its Shining Tree project in northeastern Ontario. The project, approximately 20 kilometres west of Gowganda, located in Tyrrell Township, straddles the Tyrrell Shear Zone ("TSZ") for a strike length of approximately five kilometres. The TSZ is a significant structure in the area; it and its associated structures are related to a considerable number of gold occurrences on the Goldeye property, as well as with the Temex Resources Corp. Juby Deposit (614,000 million indicated ounces of gold grading 1.36g Au/t and 602,000 inferred ounces grading 1.14 g Au/t) which is located approximately two and one-half kilometres along strike from the Goldeye boundary. Specific target areas including Hydro Creek, Gold Pit, West Zone, Cigar Lake and the West Tyrrell Iron Formation are planned to receive at least 12 holes.
Goldeye is particularly pleased to announce that it has contracted Mr. Malcolm Finlay as Coordinator of Investor Relations. Mr. Finlay has worked in Investor Relations for over 20 years, having been president of Finlay Kilgour Inc. and Finlay International Ltd. during that period. Both companies, very successfully, specialized in providing for new listings for companies planning to go public, and had a significant number of clients in the mining resource sector. Mr. Finlay will be commencing work with Goldeye immediately.
ABOUT GOLDEYE
Goldeye is a Canadian gold-focused exploration company with properties in mineral rich, politically secure jurisdictions with long traditions of mining (Canada and Chile). Goldeye's approach is to advance precious metal deposits to the development stage, employing, in part, technically advanced geophysical techniques. The qualified person (within the meaning of National Instrument 43-101) who read and approved this press release for Goldeye is Blaine R. Webster President and C.E.O. of Goldeye.
Forward Looking Statements:
This news release includes certain "forward-looking statements". Such forward-looking statements involve risks and uncertainties. The results or events predicted in these forward-looking statements may differ materially from actual results or events. The Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACT INFORMATION:
Goldeye Explorations Limited
Blaine Webster
(905) 731-9367 or (905) 886-2538
bwebster@goldeye.ca
www.goldeye.ca
An enviable financing. Any thoughts on the amount of shares OS and whether the TSE/new shareholders might require a consolidation at some point?
Former-Deputy Surgeon General Canada Appointed President Of Medizone International
Michael E. Shannon M.A., M.Sc., M.D. – One-Time Director General for the Laboratory Center for Disease Control and Deputy Surgeon General Canada, Accepts Presidential Role With Emerging Bio-Tech Star.
SAN FRANCISCO, CALIFORNIA – February 28, 2011 – Medizone International, Inc. (OTCBB:MZEI) (OTCQB:MZEI) is pleased to announce the appointment of eminent Canadian medical research scientist, Michael E. Shannon M.A.,M.Sc.,M.D., as President of the Company.
In 2008, following a distinguished government career in which he retired to pursue high-level scientific and development work in the private sector, Dr. Shannon joined the Medizone Board of Directors, immediately assuming responsibilities as Director of Medical Affairs.
Dr. Shannon will continue in his role as Director of Medical Affairs, leading the product development side of the AsepticSure™ program. This phase of the operation is being conducted with the support of our business advisor, lead engineer and renowned international medical device consultant, Bernard Lim, along with production partners, ADA Innovations.
Medizone International CEO, Edwin Marshall commented, “Dr. Shannon’s relationship with Medizone dates back many years to when he served as Director General of the Laboratory Center for Disease Control with Health Canada. He has played a pivotal leadership role in the AsepticSure™ development program. Now, with full focus on corporate growth and production, his appointment as President is a natural structural enhancement.”
The total number of people currently involved in the AsepticSure™ research, development and manufacturing program - as either employees, consultants, contractors or business support - now exceeds twenty.
Dr. Shannon added, “As the Company moves into the commercial phase of our program, I believe that my appointment as President is both timely and appropriate. Continuity will be preserved during the transition. As we expand in the months to come, my role will change to one of oversight and leadership for our technical experts as we all embrace our mandate to build quality, reliability and adaptability into a growing range of next-generation bio-oxidative products that will capture world decontamination markets by storm."
For press information on Medizone, please contact:
Jack Eversull, Investor Relations
The Eversull Group, Inc.
T: 001-972-571-1624
F: 001-214-469-2361
E: jack@theeversullgroup.com
In order to build additional shareholder value prior to anticipated partnering, merger or acquisition, Medizone International, Inc. is transitioning from pure research and product development into a multi-faceted, commercial company engaged in both the development and marketing of its AsepticSure™ System – a bio-oxidative technology designed to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, patient rooms, schools, clean rooms and other critical infrastructure. Additional variants are being developed for government use for bio-terrorism countermeasures and other commercial areas in need of disinfection technology capable of reliably delivering up to 7 log microbial kill rates.
This Press Release may contain certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues, the financial requirements of the company to achieve its business objectives, and the need for possible additional funding. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com
http://w.sharethis.com/images/facebook_32.png);">
A high today of .43 and technical indicators showing it to be Bullish in the short, mid and long term....
Abcourt Announces Non-Endorsement of Analyst Report
{"s" : "abi.be,abi.f,abi.v","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Abcourt Mines Inc. On Friday April 1, 2011, 3:14 pm EDT
MONT-ST-HILAIRE, QUEBEC--(Marketwire - April 1, 2011) - Abcourt Mines Inc. (TSX VENTURE:ABI - News; BERLIN:ABI - News; FRANKFURT:ABI - News; "Abcourt" or the "Company") announced today that it has not participated in the preparation or the review and does not in any way endorse the report from Howlett Research Corp. entitled "Abcourt Mines Inc" and dated March 28, 2011. Therefore, Abcourt does not accept nor assume any responsibility for the foregoing report and urges readers to consider such advice when reading materials that are not originating from the Company.
About Abcourt Mines Inc.
Abcourt Mines Inc. is an exploration and development company with strategically located properties in Northwestern Quebec, Canada. The Elder mine with 43-101 gold resources, the Abcourt-Barvue project with 43-101 silver-zinc ore reserves and resources and the Aldermac property with historical copper-zinc resources are all former producers. Abcourt is now focused on bringing the Elder and Abcourt-Barvue projects back in production with Elder as the first priority. At the same time, it is working on other projects (Aldermac, Jonpol and Vendome), to increase its mineral resources inventory. A 43-101 resource calculation was completed in July 2009 for the Elder mine. A positive 43-101 feasibility study was completed by GENIVAR in 2007 on the Abcourt-Barvue project. In addition, mill equipment was purchased. To know more about Abcourt, please consult our web site www.abcourt.com and SEDAR at www.sedar.com under "Abcourt Mines Inc".
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Renaud Hinse
Abcourt Mines Inc.
President and Chief Executive Officer
819-768-2857 or 450-446-5511
819-768-5475 or 450 446-3550 (FAX)
rhinse@abcourt.com